Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Direct simulation of hypertensive stress on endothelial cells: a streamlined model of in-vitro-hypertension.

Frontiers in physiology·2026
Same author

Prophylactic PDE4 and PDE4B inhibition reduce lesion size and neutrophil infiltration following ischemic stroke in male mice.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2025
Same author

USP7 at the Crossroads of Ubiquitin Signaling, Cell Cycle, and Tumorigenesis.

Molecules (Basel, Switzerland)·2025
Same author

Alzheimer's Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective.

International journal of molecular sciences·2025
Same author

Investigating the potential of the SI306 Src inhibitor and its liposomal formulation in the non-small cell lung cancer treatment.

International journal of pharmaceutics·2025
Same author

Triazole-imidazo[1,2-<i>b</i>]pyrazoles Able to Counteract Melanoma Cell Survival Without Compromising the Viability of Healthy Keratinocytes.

International journal of molecular sciences·2025

Related Experiment Videos

Novel dual Src/Abl inhibitors for hematologic and solid malignancies.

Silvia Schenone1, Chiara Brullo, Francesca Musumeci

  • 1University of Genoa, Dipartimento di Scienze Farmaceutiche, Viale Benedetto VX, Genoa, Italy. schensil@unige.it

Expert Opinion on Investigational Drugs
|June 19, 2010
PubMed
Summary

Dual Src/Abl tyrosine kinase inhibitors, like dasatinib, SKI-606, and AZD0530, show promise as targeted cancer therapies. Ongoing research explores new compounds for treating solid tumors and hematological malignancies.

Related Experiment Videos

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • c-Src and Bcr-Abl are cytoplasmic tyrosine kinases (TKs) crucial in solid and hematological malignancies.
  • Src is overexpressed in solid tumors; Bcr-Abl drives chronic myeloid leukemia (CML), with Src involvement.

Purpose of the Study:

  • To review recent advancements in dual Src/Abl tyrosine kinase inhibitors for cancer therapy.
  • To highlight the potential of targeted therapies against specific TKs.

Main Methods:

  • Review of existing literature and clinical trial data on dual Src/Abl inhibitors.
  • Focus on ATP-competitive compounds targeting Src and Abl kinases.

Main Results:

  • Dasatinib, SKI-606, and AZD0530 are key dual Src/Abl inhibitors in clinical trials.
  • Emerging compounds like AP24163, AP24534, XL228, and DC2036 show potential in preclinical studies.

Conclusions:

  • Targeted TK inhibition offers a less toxic alternative to traditional chemotherapy.
  • These inhibitors hold significant therapeutic potential, especially in combination therapies.